A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

This study has been completed.
Sponsor:
Information provided by:
XenoPort, Inc.
ClinicalTrials.gov Identifier:
NCT00838396
First received: February 5, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.


Condition Intervention Phase
GERD
Drug: arbaclofen placarbil
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease

Resource links provided by NLM:


Further study details as provided by XenoPort, Inc.:

Primary Outcome Measures:
  • The primary efficacy assessment endpoint of this study was the total number of reflux episodes (acid and non-acid) comparing study drug to placebo [ Time Frame: 12 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reflux episodes (acid and non-acid) during each treatment period at various time intervals, dose/exposure to reflux rate relationship, acid reflux events, non-acid reflux events, and GERD symptoms. [ Time Frame: 12 hours ] [ Designated as safety issue: No ]

Enrollment: 56
Study Start Date: October 2005
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Group 1 Drug: arbaclofen placarbil
After the screening/randomization visit, eligible patients were randomized to receive arbaclofen placarbil CR followed by placebo or placebo followed by arbaclofen placarbil CR
Placebo Comparator: Group 2 Drug: arbaclofen placarbil
After the screening/randomization visit, eligible patients were randomized to receive arbaclofen placarbil CR followed by placebo or placebo followed by arbaclofen placarbil CR
Placebo Comparator: Group 3 Drug: arbaclofen placarbil
After the screening/randomization visit, eligible patients were randomized to receive arbaclofen placarbil CR followed by placebo or placebo followed by arbaclofen placarbil CR
Placebo Comparator: Group 4 Drug: arbaclofen placarbil
After the screening/randomization visit, eligible patients were randomized to receive arbaclofen placarbil CR followed by placebo or placebo followed by arbaclofen placarbil CR

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. History of GERD symptoms (e.g. heartburn episodes) at least 3 times per week
  2. Discontinuation of drugs used to treat GERD (PPIs, H2-blockers) and/or drugs known to cause GERD symptoms (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs]) for 7 days prior to baseline (Visit 2);
  3. Had greater then or equal to 20 postprandial reflux episodes/2 hours recorded using impedance/pH monitoring during Screening/Baseline period (Visit 2)

Exclusion Criteria:

  1. History of gastrointestinal disorders other than GERD that may have significantly affected the assessment of reflux episodes or GERD symptoms (e.g. Barrett's Esophagus, active gastric or duodenal ulcer disease, achalasia, scleroderma, etc.).
  2. Medical conditions that could have affected assessments of reflux episodes or GERD symptoms (e.g. history of nausea and/or vomiting, neurologic/psychiatric disorders, cardiac disease [e.g. angina], lung disease [e.g. asthma, cough], etc.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00838396

Locations
United States, California
Stanford, California, United States, 94305
United States, South Carolina
Charleston, South Carolina, United States, 29425
United States, Washington
Tacoma, Washington, United States, 98403
Sponsors and Collaborators
XenoPort, Inc.
Investigators
Study Director: Jay Huff, M.D. XenoPort, Inc.
  More Information

No publications provided

Responsible Party: Jay Huff, M.D, Vice President, Clinical Development, XenoPort, Inc.
ClinicalTrials.gov Identifier: NCT00838396     History of Changes
Other Study ID Numbers: XP-B-049
Study First Received: February 5, 2009
Last Updated: February 5, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Gastroesophageal Reflux
Deglutition Disorders
Digestive System Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases
Arbaclofen placarbil
Baclofen
Central Nervous System Agents
GABA Agents
GABA Agonists
GABA-B Receptor Agonists
Molecular Mechanisms of Pharmacological Action
Muscle Relaxants, Central
Neuromuscular Agents
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014